Exelixis, Inc. (Nasdaq: EXEL) announced that enrollment is now completed for CONTACT-01, the global, phase 3 pivotal trial evaluating cabozantinib (CABOMETYX?) in combination with atezolizumab (TECENTRIQ?) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. CONTACT-01 is a global, multicenter, randomized, phase 3, open-label study that enrolled 366 patients who were randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab and the control arm of docetaxel. The primary endpoint of the trial is overall survival. Secondary endpoints include progression-free survival, objective response rate and duration of response. Results from cohort 7 of the phase 1b COSMIC-021 trial informed the CONTACT-01 trial design. CONTACT-01 is sponsored by Roche and co-funded by Exelixis. More information about the trial is available at ClinicalTrials.gov.